

### DISCLAIMER



This Presentation (the "Presentation") is provided on a strictly informational basis only. By reviewing or reading this Presentation, you will be deemed to have agreed to the obligations and restrictions set out below. Without the express prior written consent of SPAC Alpha, the Presentation and any information contained within it may not be (i) reproduced (in whole or in part), (ii) copied at any time, (iii) used for making investment decisions. This Presentation does not constitute or form part of, and should not be construed as, an offer, invitation or inducement to purchase or subscribe for securities nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation does not constitute either advice or a recommendation regarding any securities. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law in no circumstances will SPAC Alpha, or any of its respective subsidiaries, shareholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents (including economic models or any other materials from SPAC Alpha), its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. The information contained in this Presentation has not been independently verified. Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with SPAC Alpha or its representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all the information related to the subject matter. Recipients of this Presentation should each make their own evaluation of the subject matter and of the relevance and adequacy of the information and should make such other investigations as they deem necessary.

This Presentation contains illustrative returns, projections, estimates and beliefs and similar information ("Forward Looking Information"). Forward Looking Information is subject to inherent uncertainties and qualifications and is based on numerous assumptions, in each case whether or not identified in the Presentation. Forward Looking Information is provided for illustrative purposes only and is not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Nothing in this Presentation should be construed as a profit forecast. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Some important factors that could cause actual results to differ materially from those in any Forward-Looking Information could include changes in domestic and foreign business, market, financial, political, and legal conditions. There can be no assurance that any Forward-Looking Information will be realized, and the performance may be materially and adversely different from the Forward-Looking Information. The Forward-Looking Information speaks only as of the date of this Presentation. SPAC Alpha expressly disclaims any obligation or undertaking to release any updates or revisions to any Forward Looking Information to reflect any change in SPAC Alpha's expectations with regard thereto or any changes in events, conditions or circumstances on which any Forward Looking Information is based. Accordingly, undue reliance should not be placed upon the Forward-Looking Information.

The communication of this Presentation is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. This Agreement supersedes and replaces all previous oral or written agreements, memoranda, correspondence, or other communications between the parties hereto relating to the subject matter hereof.

### SPAC OVERVIEW



# Special Purpose

Special Purpose Acquisition Companies (SPACs) are formed with the specific purpose of acquiring one or more unspecified businesses or assets using proceeds from an Initial Public Offering (IPO) and Private Placement(s).

# **Corporate Structure**

- Domestic C-corporation or a Foreign Private Issuer based in Cayman/BVI listed on the NYSE or Nasdaq exchange.
- Not the same as "Blank Check" companies exempt from Rule 419.
- IPO units are priced at \$10 and include warrants/rights along with a common share. IPO proceeds are held in independently run Trust Account.
- Abide by SEC and Stock Exchange rules around disclosures and corporate governance like any other listed C-corp
- Require Board and Shareholder approval to consummate an acquisition

#### **Transaction**

- Cannot engage in "material" discussions with a potential target or lock up a transaction in advance of the IPO – this would trigger SEC disclosure.
- Depending on IPO terms, a SPAC has 18–24 months to consummate an acquisition - this period can be extended up to a maximum of 36 months with shareholder approval.
- Fair Market Value of initial transaction must be at least 80% of the assets held in the Trust Account (excluding the deferred underwriting discount and taxes payable on the interest earned in the Trust Account)

# SPACs COMPARED TO VC/PE/HEDGE FUNDS



	VC/PE/Hedge Funds	SPACs				
Investment Capital	<ul> <li>Based on the team's track record in investments and creating portfolio value</li> <li>Investments are not pre-identified (blind pool)</li> </ul>					
Investment Portfolio	<ul><li>20-25 positions</li><li>More diversified for Hedge Funds</li></ul>	<ul> <li>Usually a single transaction</li> <li>Sometimes, multiple acquisitions either as initial business combination or serially</li> </ul>				
Transaction Sizing	Investment size = Investment capital divided by number of portfolio positions	Investment size = 2-3x of IPO proceeds but no upper limit				
Management Fees	1-2% of committed capital	None				
Upside Sharing	20% of profits (carried interest)	20% of post-IPO equity				
Investment Duration	<ul> <li>VC/PE: 7 years but can be extended to 9-10 years with LP approval</li> <li>Hedge funds: 1 month to 3-year liquidity depending on strategy</li> </ul>	<ul> <li>Usually 18-24 months</li> <li>Can be extended to 36 months with shareholder approval</li> </ul>				
Investment Liquidity	<ul> <li>LP interests have limited liquidity</li> <li>VC/PE: first money in to last money out can take 10+ years</li> </ul>	Lock-up: • IPO shares: none • Pre-IPO shares: until transaction closing • Sponsor shares: 1 year after transaction closing				

# SPAC: BENEFITS FOR SELLERS AND INVESTORS



### **Benefits for the Seller**


- Fast track to public market listing
- Less disruptive to Seller/TargetCo employees than traditional IPO
- Ability to provide forward guidance on business prospects in proxy filing
- Potential for seller to retain upside through stock consideration
- Ability to structure transactions to meet seller's specific needs
- Flexible capital can use mezzanine debt, senior debt, convertible preferred shares, etc.
- Benefit from Sponsor's management experience and credibility with investors
- Private equity type deal without private equity rights/terms

### **Benefits for the Investor**

- Access to aligned high quality sponsors without management fees
- Private equity-like investment
- Capital protection using ring-fenced trust account that provides investors with redemption right at Closing
- Alignment of interest through sponsor risk capital (pre-IPO)
- Immediate liquidity though publicly traded securities
- Equity exposure through common stock investment
- Additional upside through warrants
- Bounded time horizon wind-up with 100% principal returned to investors if no acquisition within 24 months

# SPAC: CORPORATE STRUCTURE





# SPAC: BALANCE SHEET STRUCTURE



### **Illustrative Example**

Pre-Deal Closing

Post-Deal Closing

Shareholders	\$M	Shares	%
SPAC sponsor	50	5.0	20
Pre-IPO investors*	6	0.6	2
IPO investors*	200	20.0	78
Total equity	256	25.6	100

TargetCo equity: \$750M


Shareholders	\$M	Shares	%
SPAC sponsor	50	5.0	5
Pre-IPO investors*	6	0.6	1
IPO investors*	200	20.0	20
TargetCo owners	750	75.0	75
Total equity	1,006	100.6	100

Most SPAC deals are minority transactions on account of SPAC equity consideration.

Control SPAC transactions have significant secondary or leverage reduction components.

# SPAC: PROCESS TIMELINE BY STAGE





# SPAC IPO PROCESS OVERVIEW



### 1. Organizational Preparation

- Finalize team roles and independent directors
- Complete pre-IPO placement
- Hire banking syndicate, issuer's counsel, accountant, auditor, financial printer and trust agent
- Form corporate entity: draft charter, bylaws, code of ethics, corporate policies
- Director & Officers questionnaire, background checks, D&O insurance, power of attorney for registration statement/amendments, open bank account, Board resolutions

#### 2. IPO Documentation

- Prepare financial statements
- Audit financials and draft auditor's comfort letter
- Issuer's counsel drafts S-1 registration statement with input from Underwriter's counsel
- Draft underwriting letter and insider letter
- With underwriters, draft IPO roadshow presentation
- Commence Blue Sky qualification and FINRA approval process

### 3. Filing and Roadshow

- File S-1 and respond to SEC comments through amendments until final S-1 prospectus
- Management presentation to underwriter's sales force
- Notify FINRA of effective and offering date
- Underwriting agreement and comfort letter
- Board approval of final prospectus, underwriting agreement
- Complete roadshow. Agree on final terms and allocation

# SPAC POST-IPO PROCESS OVERVIEW



### 4. SEC & Exchange Requirements

- File quarterly (10Q) and annual (10k) financial statements
- File US and franchise taxes if domiciled domestically
- Issue 8K in the event of any material developments
- Hold regular Board meetings

### 5. Transaction (3-6 months)

- Engage with multiple target companies to assess attractiveness
- Enter into non-binding LOI to initiate due diligence non-binding agreements are not subject to 8K disclosure requirement
- As part of diligence process, take select investors "over the wall" to gauge investor interest
- Begin definitive documentation
- Arrange PIPE and/or debt financing
- Board approval for transaction
- Execute definitive merger documentation along with PIPE agreements
- Announce transaction 8K and press release
- Proxy filing with the SEC typically takes 2 months from initial filing to effective (final) version
- Conduct roadshow to educate investors about investment opportunity

### 6. Closing

- Schedule shareholder vote with at least 3 weeks notice after Proxy effectiveness
- Shareholder vote to approve transaction and related corporate actions
- Following successful Shareholder vote & Closing, the PIPE proceeds and SPAC Trust assets are available to merged entity after accounting for redemptions
- Liquidate SPAC if majority vote is negative or conditions precedent to Closing are not met
- New corporate identity change in management/board members, name and ticker symbol, etc.
- File Super 8K

## BEST PRACTICES IN SPAC TRANSACTIONS



### **Target Selection**

- Focus on targets with equity value at least >2-3x of SPAC IPO:
  - Ensures that the merged entity will be large enough for public markets
  - Reduces sponsor dilution to under 10%
- Negative list:
  - Sectors where the SPAC team has no experience
  - Contrarian bets or businesses with no/inadequate listed comparable peers
  - Activist/hostile situations
  - Distressed company distressed businesses don't go public
  - Businesses with accounting irregularities, significant legal/anti-trust issues, regulatory overhang, complex shareholder structure with veto rights or unclear drag/tag rights

### **Transaction Structuring**

- Valuation:
  - If the valuation is in line with listed peers, investors would prefer to invest in companies with long public track records and more information around liquidity (ADTV) good transactions factor in public/private valuation arbitrage
  - Attractive transactions are priced well relative to other listed options
- Secondary component:
  - Transactions involving significant investor cash-out require higher investment conviction which
    is (only) validated by investment from TargetCo management and/or fundamental investors
  - Ideal SPAC transactions have high degree of equity rolled over by existing shareholders to support the premise that there is significant investment upside
- Conditions to Closing:
  - Onerous conditions to closing result in "merger arbitrage" overwhelming fundamental interest
  - Cash condition to closing should be addressed through PIPE/debt financing or by locking in requisite public investors ideally before definitive agreement this reduces the merger arb dynamic and focuses attention on the fundamental merits of the TargetCo
- Investor communication before the shareholder vote is critical



# US SPAC INDUSTRY MACRO ANALYSIS

## SPAC IPOS HAVE GROWN RAPIDLY



### IPOs excluding SPACs/Funds\*, \$billion



2012 2013 2014 2015 2016 2017 2018 2019 2020

### **SPAC IPOs, \$billion**



2012 2013 2014 2015 2016 2017 2018 2019 2020

### Number of IPOs excluding SPACs/Funds\*



2012 2013 2014 2015 2016 2017 2018 2019 2020


#### **Number of SPAC IPOs**



<sup>013 2014 2013 2010 2017 2010 2013 2020 2012 2013 2014 2013 2010 2017 2010 2013 2020</sup> 


# MARKET SHARE OF SPACs VERSUS ALL IPOS





# TREND IN AVERAGE SIZE OF SPAC IPOS





# NUMBER OF SPACs: BY GEOGRAPHIC FOCUS



Region*	2015	2016	2017	2018	2019	2020	Total Number	% Share
North America/ Generalist	14	12	30	35	48	24	163	82%
Asia	3	1	3	6	6	3	22	11%
Latin America	2	0	0	3	4	0	9	5%
Europe	1	0	1	2	1	1	6	3%
Total	20	13	34	46	59	28	200	100%

<sup>\*</sup> Classified by HQ location of acquisition target, or by disclosure in S-1 filing if no deal announced Data source: SPAC Research

# NUMBER OF SPACs: BY SECTOR FOCUS



Industry*	2015	2016	2017	2018	2019	2020	Total Number	% Share
TMT	4	3	7	7	12	8	41	21%
Generalist	3	1	0	10	13	12	39	20%
Consumer	5	2	9	6	14	2	38	19%
Healthcare	0	1	5	4	6	4	20	10%
Industrials	3	2	4	5	5	0	19	10%
Energy	1	2	8	4	3	0	18	9%
Financials	2	2	1	6	5	0	16	8%
Other	2	0	0	4	1	2	9	5%
Total	20	13	34	46	59	28	200	100%

<sup>\*</sup> Classified by industry sector of acquisition target, or by disclosure in S-1 filing if no deal announced Data source: SPAC Research

# SPACs: STAGEWISE STRATIFICATION



US-listed SPACs, launched 2015-2020	Number	% Share
Liquidated without a transaction	9	4.5%
Closed a transaction	82	41.0%
Transaction stage	109	54.5%
Total US-listed SPACs	200	100.0%
Pre-IPO (S-1 filed)	5	

Data source: SPAC Research

# SPAC TRANSACTIONS: PERFORMANCE



US-listed SPACs, launched 2015-2020	Number	Average Total Price <sup>1</sup>
All SPAC transactions	82	\$9.5
All US transactions	65	\$10.3
Ex-US transactions (principally China)	17	<b>\$5.6</b>

<sup>1.</sup> Total Price = (Price of Common share + Warrant coverage) at 365 days from Closing or sooner for deals that closed less than a year ago. Data source: SPAC Research

# SPAC TRANSACTIONS: PERFORMANCE



US-listed SPACs, launched 2015-2020	Number	Average Total Price <sup>2</sup>
SPACs with transactions in Energy	8	\$8.6
Ex-US transactions (principally China)	17	\$5.6
SPACs with Rights in IPO unit	19	\$4.4
Adverse SPACs <sup>1</sup>	34	\$6.2
SPACs with US deals ex-Energy/ex-Rights	48	\$11.9

<sup>1.</sup> Adverse SPACs defined as SPACs that closed energy/ex-US transaction or with Rights in their IPO Unit.

<sup>2.</sup> Total Price = (Price of Common share + Warrant coverage) at 365 days from Closing or sooner for deals that closed less than a year ago. Data source: SPAC Research

# SPAC TRANSACTIONS: PERFORMANCE



US-listed SPACs, launched 2015-2020	Number	Average Total Price <sup>2</sup>
SPACs with US deals ex-Energy/ex-Rights	48	\$11.9
- Top quartile SPACs <sup>1</sup>	12	\$23.8
- 2 <sup>nd</sup> quartile SPACs <sup>1</sup>	12	\$12.4
- 3 <sup>rd</sup> quartile SPACs <sup>1</sup>	12	\$8.0
- Bottom quartile SPACs <sup>1</sup>	12	\$3.6

US SPAC deals (ex-Energy/ex-Rights)

Top half: \$18.1

Bottom half: \$5.8



<u>Top 50%</u> = Bottom 50%



<sup>1.</sup> SPACs that closed a US transaction excluding energy sector and those with Rights in their IPO Unit.

<sup>2.</sup> Total Price = (Price of Common share + Warrant coverage) at 365 days from Closing or sooner for deals that closed less than a year ago. Data source: SPAC Research

# DID TOP PERFORMING SPACs HAVE FPAs?



US-listed SPACs, launched 2015-2020	Number	Average Total Price <sup>2</sup>	Forward Purchase Agreement (FPA) <sup>3</sup>
SPACs with US deals ex-Energy/ex-Rights	48	\$11.9	8
- Top quartile SPACs <sup>1</sup>	12	\$23.8	2
- 2 <sup>nd</sup> quartile SPACs <sup>1</sup>	12	\$12.4	1
- 3 <sup>rd</sup> quartile SPACs <sup>1</sup>	12	\$8.0	5
- Bottom quartile SPACs <sup>1</sup>	12	\$3.6	0
Adverse SPACs <sup>4</sup>	34	\$6.2	3
SPACs, transaction stage	109	tbd	23

<sup>1.</sup> SPACs that closed a US transaction excluding energy sector and those with Rights in their IPO Unit.

<sup>2.</sup> Total Price = (Price of Common share + Warrant coverage) at 365 days from Closing or sooner for deals that closed less than a year ago.

<sup>3.</sup> Transactions where an equity or convertible equity FPA was deployed.

<sup>4.</sup> Adverse SPACs defined as SPACs that closed energy/ex-US transaction or with Rights in their IPO Unit Data source: SPAC Research

# HOW WELL DID INVESTORS PICK WINNERS?



US-listed SPACs, launched 2015-2020	Number	Average Total Price <sup>2</sup>	Redemption at Closing <sup>3</sup>
- Top quartile SPACs <sup>1</sup>	12	\$23.8	23%
- 2 <sup>nd</sup> quartile SPACs <sup>1</sup>	12	\$12.4	45%
- 3 <sup>rd</sup> quartile SPACs <sup>1</sup>	12	\$8.0	48%
- Bottom quartile SPACs <sup>1</sup>	12	\$3.6	70%
SPACs with transactions in Energy	8	\$8.6	40%
Ex-US transactions (principally China)	17	\$5.6	79%
SPACs with Rights in IPO unit	19	\$4.4	88%

<sup>1.</sup> SPACs that closed a US transaction excluding energy sector and those with Rights in their IPO Unit.

<sup>2.</sup> Total Price = (Price of Common share + Warrant coverage) at 365 days from Closing or sooner for deals that closed less than a year ago.

<sup>3.</sup> Redemption at closing by common shareholders. This does not factor in "churn" in shareholders before Closing. Data source: SPAC Research

# SPAC DEALS: HALL OF FAME

SPAC alpha

Set of 200 SPACs that went public between 2015-2020

Set of 200 SPACS	criac weric	равне весте	EN 2015 202						
SPAC	IPO, \$M	Lead Left	Seller	Target (Ticker)	Target Sector	Deal Year	Select Investors	EV, \$B <sup>1</sup>	Total Price <sup>2</sup>
Diamond Eagle Acq	\$400	Deutsche Bank	Founders	Draft Kings (DKNG)	TMT	2020	Capital Research, Wellington, Franklin Templeton	\$12.1	\$36.6
Thunder Bridge Acq	\$258	Cantor	Corsair Capital	Repay Holdings (RPAY)	Financials	2019	BlackRock, Neuberger Berman, Baron Funds, Monroe Capital	\$2.0	\$27.9
Churchill Capital	\$690	Citigroup	Onex, Baring PE	Clarivate (CCC)	TMT	2019	Michael Klein, Jerre Stead	\$9.9	\$26.8
Health Sciences Acq	\$115	Chardan	Roivant	Immunovant (IMVT)	Healthcare	2019	RTW Investments, BVF Partners	\$1.6	\$27.2
DFB Healthcare Acq	\$250	Goldman Sachs	BlueMoun tain	AdaptHealth (AHCO)	Healthcare	2019	Deerfield	\$1.6	\$19.3
FinTech Acq Corp	\$100	Cantor	FTV Capital	CardConnect (CCN)	Financials	2016	Falcon Strategic Partners	\$0.8 (acq)	\$18.6
Social Capital Hedosophia	\$690	Credit Suisse	Virgin Group	Virgin Galactic (SPCE)	Consumer	2019	Boeing, Chamath Palihapitya	\$3.2	\$18.8
Conyers Park Acq Corp	\$403	Deutsche Bank	Roark Capital	Simply Good Foods (SMPL)	Consumer	2017	Fidelity, Capital Research, T. Rowe	\$2.2	\$17.3
Double Eagle Acq	\$500	Deutsche Bank	Algeco Scotsman	WillScot (WSC)	Industrial	2017	TDR Capital	\$3.4	\$16.2
Gores Holdings II	\$400	Deutsche Bank	Platinum Equity	Verra Mobility (VRRM)	TMT	2018	GIC, Hamilton Lane, Northwestern Mutual	\$2.5	\$15.9

<sup>1.</sup> EV as of May 29, 2020

<sup>2.</sup> Total Price = (Price of Common share + Warrant coverage) at 365 days from Closing or sooner for deals that closed less than a year ago Data source: SPAC Research

# 9 OF 200 SPACS LIQUIDATED TO DATE

SPAC alpha

Set of 200 SPACs that went public between 2015-2020

Name	Sponsor or Affiliate	Underwriters	IPO Proceeds \$M	IPO Unit	Sector	Geography	Deal?	IPO Date	Liquidated
Barington /Hilco Acq	Israel Abramowitz	EarlyBirdCapital, Aegis, I-Bankers	\$43	W/2 +1/10R	Consumer	US	Oomba, Inc	Feb 2015	Nov 2018
Atlantic Alliance Partnership	Lepe Partners, Mark Klein	Citigroup, Maxim, I-Bankers	\$77	105% in Trust, No Warrants	ТМТ	Europe	Kalyx Cannabis REIT	Apr 2015	Nov 2017
Electrum Special Acq	Thomas Kaplan	Cantor, Brock	\$200	W/2	Gold Mining	Global	No	Jun 2015	Jun 2018
Saban Capital Acq	Haim Saban	Deutsche Bank, Goldman Sachs	\$250	W/2	TMT	Israel	Panavision	Sep 2016	Mar 2019
Vantage Energy Acq	NGP Energy Capital	Citigroup, Credit Suisse, Goldman Sachs	\$552	W/3	Energy	NA	Williston Basin Assets of QEP Resources	Apr 2017	Apr 2019
Sentinel Energy	CSL Capital	Citigroup, Goldman Sachs, Credit Suisse	\$345	W/3	Energy	NA	Strike, Inc (\$110M inv by Fidelity)	Nov 2017	Nov 2019
Regalwood Global Energy	Carlyle	Citigroup, JPMorgan	\$300	W/3	Energy	Global	No	Dec 2017	Dec 2019
Allegro Merger	Eric Rosenfeld (6 <sup>th</sup> SPAC)	Cantor, Chardan, I-Bankers	\$150	W/2 +1/10R	Generalist	Global	TGI Fridays	Jun 2018	Apr 2020
Fellazo, Inc.		Maxim	\$58	W/2 + 1/10R	Consumer	Asia	No	Jul 2019	Jul 2020

Data source: SPAC Research



# US SPAC INDUSTRY LEAGUE TABLES

# UNDERWRITERS: 2015-2020 LEADERS



Rank	Underwriters Volume Sold, \$M*	2015	2016	2017	2018	2019	2020	Total Value	% share
1	Credit Suisse	\$33	\$413	\$1,639	\$914	\$1,286	\$2,372	\$6,656	13%
2	Citigroup	\$1,059	\$888	\$1,520	\$1,133	\$960	\$1,029	\$6,589	13%
3	Deutsche Bank	\$1,202	\$634	\$1,307	\$872	\$1,270	\$753	\$6,038	12%
4	Cantor	\$708	\$218	\$841	\$1,204	\$2,574	\$150	\$5,695	11%
5	Goldman Sachs		\$302	\$684	\$711	\$865	\$1,010	\$3,572	7%
6	EarlyBirdCapital	\$189	\$91	\$761	\$884	\$632	\$216	\$2,772	5%
7	BofA Merrill Lynch	\$226	\$240	\$160	\$643	\$194	\$576	\$2,039	4%
8	B. Riley FBR			\$289	\$573	\$556	\$216	\$1,633	3%
9	Chardan		\$39	\$101	\$766	\$238	\$195	\$1,339	3%
10	Jefferies		\$106		\$518	\$395	\$216	\$1,235	2%

<sup>\*</sup> Volume sold as per SEC filings. Does not include greenshoe amount. B. Riley + FBR shown for B. Riley FBR Data source: SPAC Research

# UNDERWRITERS: LEAGUE TABLE YTD 5/2020

### SPAC alpha

Rank by Vol Sold	Underwriters	Bookrunner Volume, \$M¹	% Share	Bookrunner Count	% Share	Volume Sold, \$M²	% Share
1	Credit Suisse	\$2,428	26.5%	6	21.4%	\$2,372	25.9%
2	Citigroup	\$1,080	11.8%	3	10.7%	\$1,029	11.2%
3	Goldman Sachs	\$1,148	12.5%	4	14.3%	\$1,010	11.0%
4	Deutsche Bank	\$749	8.2%	4	14.3%	\$753	8.2%
5	BofA Merrill Lynch	\$588	6.4%	2	7.1%	\$576	6.3%
6	UBS	\$510	5.6%	4	14.3%	\$324	3.5%
7	Morgan Stanley	\$558	6.1%	3	10.7%	\$274	3.0%
8	EarlyBirdCapital	\$342	3.7%	2	7.1%	\$216	2.4%
9	Jefferies	\$277	3.0%	2	7.1%	\$216	2.4%
10	B. Riley FBR	\$175	1.9%	1	3.6%	\$216	2.4%
11	Chardan	\$201	2.2%	3	10.7%	\$195	2.1%
12	Cowen	\$180	2.0%	1	3.6%	\$180	2.0%
13	Cantor Fitzgerald	\$150	1.6%	1	3.6%	\$150	1.6%
14	Nomura	\$100	1.1%	1	3.6%	\$147	1.6%
15	Imperial Capital	\$173	1.9%	1	3.6%	\$120	1.3%
16	I-Bankers	\$138	1.5%	1	3.6%	\$120	1.3%
17	Maxim	\$69	0.8%	1	3.6%	\$90	1.0%
18	RBC	\$115	1.3%	1	3.6%	\$75	0.8%
19	Oppenheimer	\$100	1.1%	1	3.6%	\$68	0.7%
20	Roth Capital	\$38	0.4%	1	3.6%	\$38	0.4%

<sup>1.</sup> Credit for Bookrunner Volume is awarded to the sole bookrunner or split equally among joint bookrunners

<sup>2.</sup> Volume sold as per SEC filings. Does not include greenshoe amount. B. Riley + FBR shown for B. Riley FBR Data source: SPAC Research

# UNDERWRITERS: LEADERS BY IPO SIZE



### **SPACs under \$100M, 2015-2020**

Rank	Underwriters	Volume Sold, \$M*	% Share
1	EarlyBirdCapital	\$633	32%
2	Chardan	\$559	28%
3	Maxim	\$337	17%
4	Cantor Fitzgerald	\$130	7%
5	I-Bankers	\$130	7%
6	Citigroup	\$73	4%
7	Craig-Hallum	\$38	2%
8	Roth	\$38	2%
9	B. Riley FBR	\$21	1%
10	Aegis	\$14	1%

### SPACs between \$100-300M, 2015-2020

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Cantor Fitzgerald	\$3,166	18%
2	EarlyBirdCapital	\$1,764	10%
3	Credit Suisse	\$1,738	10%
4	Deutsche Bank	\$1,334	8%
5	B. Riley FBR	\$1,267	7%
6	Jefferies	\$902	5%
7	Citigroup	\$825	5%
8	Chardan	\$769	4%
9	BTIG	\$711	4%
10	Cowen	\$586	3%

**Top 5 players account for 91% share** 

Top 5 players account for 52% share

<sup>\*</sup> Volume sold as per SEC filings. Does not include greenshoe amount. B. Riley + FBR shown for B. Riley FBR Data source: SPAC Research

# UNDERWRITERS: LEADERS BY IPO SIZE



### **SPACs above \$300M, 2015-2020**

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Citigroup	\$5,691	21%
2	Credit Suisse	\$4,919	18%
3	Deutsche Bank	\$4,704	18%
4	Goldman Sachs	\$2,997	11%
5	Cantor Fitzgerald	\$2,398	9%
6	BofA	\$1,778	7%
7	UBS	\$543	2%
8	Morgan Stanley	\$516	2%
9	J.P. Morgan	\$384	1%
10	EarlyBirdCapital	\$375	1%

### Aggregate SPAC IPOs, 2015-2020

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Credit Suisse	\$6,656	14%
2	Citigroup	\$6,589	14%
3	Deutsche Bank	\$6,038	13%
4	Cantor Fitzgerald	\$5,695	12%
5	Goldman Sachs	\$3,572	8%
6	EarlyBirdCapital	\$2,772	6%
7	BofA	\$2,039	4%
8	B. Riley FBR	\$1,635	3%
9	Chardan	\$1,339	3%
10	Jefferies	\$1,235	3%

### **Top 5 players account for 78% share**

Top 5 players account for 62% share

<sup>\*</sup> Volume sold as per SEC filings. Does not include greenshoe amount. B. Riley + FBR shown for B. Riley FBR Data source: SPAC Research

# UNDERWRITERS: SECTOR LEADERS



### **TMT SPACs**, 2015-2020

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Credit Suisse	\$2,369	23%
2	Citigroup	\$1,725	17%
3	Cantor Fitzgerald	\$1,399	13%
4	Deutsche Bank	\$1,058	10%
5	BofA Merrill Lynch	\$795	8%
6	EarlyBirdCapital	\$590	6%
7	B. Riley FBR	\$390	4%
8	BTIG	\$289	3%
9	Goldman Sachs	\$266	3%
10	UBS	\$175	2%

### Consumer SPACs, 2015-2020

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Deutsche Bank	\$1,636	19%
2	Cantor Fitzgerald	\$1,430	17%
3	Credit Suisse	\$1,069	13%
4	EarlyBirdCapital	\$976	11%
5	Goldman Sachs	\$764	9%
6	Citigroup	\$572	7%
7	Jefferies	\$381	4%
8	B. Riley FBR	\$195	2%
9	BTIG	\$185	2%
10	I-Bankers	\$184	2%

### Top 5 players account for 71% share

Top 5 players account for 69% share

<sup>\*</sup> Volume sold as per SEC filings. Does not include greenshoe amount. B. Riley + FBR shown for B. Riley FBR Data source: SPAC Research

# UNDERWRITERS: SECTOR LEADERS



### Financials SPACs, 2015-2020

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Cantor Fitzgerald	\$1,082	32%
2	Citigroup	\$418	12%
3	B. Riley FBR	\$391	12%
4	Morgan Stanley	\$288	8%
5	Deutsche Bank	\$250	7%
6	BofA Merrill Lynch	\$240	7%
7	Chardan	\$180	5%
8	Credit Suisse	\$120	4%
9	Barclays	\$110	3%
10	I-Bankers	\$75	2%

### Healthcare SPACs, 2015-2020

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Credit Suisse	\$676	20%
2	UBS	\$349	10%
3	Chardan	\$329	10%
4	Cowen	\$290	9%
5	Citigroup	\$240	7%
6	Cantor Fitzgerald	\$220	7%
7	Deutsche Bank	\$175	5%
8	Jefferies	\$166	5%
9	BofA Merrill Lynch	\$160	5%
10	Goldman Sachs	\$125	4%

**Top 5 players account for 72% share** 

Top 5 players account for 57% share

<sup>\*</sup> Volume sold as per SEC filings. Does not include greenshoe amount. B. Riley + FBR shown for B. Riley FBR Data source: SPAC Research

# UNDERWRITERS: SECTOR LEADERS



### **Energy SPACs, 2015-2020**

Rank	Underwriters	Volume Sold, \$M*	% Share
1	Citigroup	\$1,533	26%
2	Credit Suisse	\$1,099	19%
3	Goldman Sachs	\$824	14%
4	Deutsche Bank	\$705	12%
5	EarlyBirdCapital	\$294	5%
6	BTIG	\$231	4%
7	Oppenheimer	\$175	3%
8	Chardan	\$168	3%
9	Maxim	\$126	2%
10	J.P. Morgan	\$120	2%

### **Industrials SPACs, 2015-2020**

Rank	Underwriters	Volume Sold, \$M*	% Share	
1	Cantor Fitzgerald	\$513	11%	
2	Citigroup	\$502	11%	
3	Goldman Sachs	\$480	11%	
4	Deutsche Bank	\$469	10%	
5	BofA Merrill Lynch	\$425	9%	
6	UBS	\$379	8%	
7	Credit Suisse	\$303	7%	
8	B. Riley FBR	\$200	4%	
9	Stifel	\$162	4%	
10	Nomura	\$159	4%	

**Top 5 players account for 76% share** 

Top 5 players account for 53% share

<sup>\*</sup> Volume sold as per SEC filings. Does not include greenshoe amount. B. Riley + FBR shown for B. Riley FBR Data source: SPAC Research

# ISSUER'S COUNSEL: LEAGUE TABLE



### Number of SPAC IPOs

Rank	Legal Counsel	2015	2016	2017	2018	2019	2020	Total Number
1	Ellenoff Grossman & Schole	5	4	11	16	21	3	60
2	Graubard Miller	6		2	5	8	2	23
3	Winston & Strawn		3	1	4	4	5	17
4	Loeb & Loeb		1	2	3	5	4	15
5	Weil, Gotshal & Manges	2	2	5	1	1	3	14
6	Kirkland & Ellis			1	2	4	3	10
7	Greenberg Traurig	2		1	5	2		10
8	Skadden, Arps, Slate, Meagher & Flom	2	1	1	1	1	3	9
9	Ledgewood PC	1		2	1	2		6
10	Paul, Weiss, Rifkind, Wharton & Garrison			1	1	2	1	5

Data source: SPAC Research

# **AUDITOR: LEAGUE TABLE**



### Number of SPAC IPOs

Rank	Auditor	2015	2016	2017	2018	2019	2020	Total Number
1	Marcum	11	5	15	19	29	13	92
2	Withum	5	5	13	18	21	13	75
3	KPMG	2	2	3	1	1	1	10
4	Grant Thornton				1	4		5

Data source: SPAC Research

# CONSTELLATION alpha

### **Insights**

### Investments

### SPAC Research

Leader in SPAC industry information services

SPAC Alpha

SPAC analysis and advisory services

### Co-sponsor SPACs through:

- · Risk capital investments
- Turnkey platform to enable dealmaker to focus on Closing
- Participate on Team & Board to drive successful outcomes

### **SPACs**

# DMTK up ~100% since Closing

- Sponsored & led SPAC that raised ~\$144M in Nasdaq IPO
- Closed DermTech acquisition on 8/29/19.
- Shareholders rolled over equity at \$6.50 per share.
- Pre and Post-Closing PIPEs totaling ~\$94M at weighted average price of ~\$9.00/share

SPAC (H2 2020)

For more insights, visit us on spacalpha.com

### **Contact Us:**

- Information Services <u>info@spacresearch.com</u>
- Analysis & Advisory info@spacalpha.com
- Investments <a href="mailto:cosponsor@constellationalpha.com">cosponsor@constellationalpha.com</a>